Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10146037 | 0.78 | GPR84 (0.49) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL15008847 | 0.73 | ALDH1A1 (0.45) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL8360107 | 0.72 | GGPS1 (0.53) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL9797098 | 0.72 | GGPS1 (0.56) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL5755912 | 0.72 | GGPS1 (0.53) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL2017760 | 0.72 | GGPS1 (0.53) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL18265799 | 0.72 | GGPS1 (0.53) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL30456726 | 0.72 | SSTR4 (0.49) | GGPS1FDPSDRD4DRD3IRAK4 | |
| Hydrochloric Acid SCHEMBL5655467 | 0.70 | GGPS1 (0.55) | GGPS1FDPSDRD4DRD3GPR84 | |
| Hydrochloric Acid SCHEMBL2180991 | 0.70 | GGPS1 (0.51) | GGPS1FDPSDRD4DRD3GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | GGPS1 2663/4885FDPS 2211/4885DRD4 347/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | GGPS1 2239/4885FDPS 2095/4885DRD4 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.